Florida is currently home to 3762 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Nephrotic Syndrome Study Network
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: University of Miami Miller School of Medicine, Miami, Florida
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Recruiting
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/17/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Healthy Participants
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Vida Clinical Research, Kissimmee, Florida
Conditions: Psoriatic Arthritis, Overweight or Obesity
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Recruiting
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida
Conditions: Rheumatoid Arthritis
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Alliance for Multispecialty Research, LLC, Fort Myers, Florida
Conditions: Psoriasis, Overweight or Obesity
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Recruiting
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
04/17/2025
Locations: Research Centers of America ( Hollywood ), Hollywood, Florida
Conditions: Alcohol Use Disorder
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Recruiting
The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Hepatic Insufficiency, Healthy
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Recruiting
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/17/2025
Locations: QPS-MRA, LLC ( Site 0012), Miami, Florida
Conditions: Healthy
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
Recruiting
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/17/2025
Locations: Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale Beach, Florida
Conditions: Healthy
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Northeast Research Institute (NERI), Fleming Island, Florida
Conditions: Obesity, Overweight
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
Recruiting
The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/17/2025
Locations: James A Haley Veteran Affairs Medical Center - NAVREF - PPDS, Tampa, Florida
Conditions: Acute Kidney Injury
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Recruiting
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/17/2025
Locations: Driven Research, Coral Gables, Florida
Conditions: Plaque Psoriasis